SI-BONE, Inc. (NASDAQ:SIBN) Shares Sold by Champlain Investment Partners LLC

Champlain Investment Partners LLC lessened its holdings in shares of SI-BONE, Inc. (NASDAQ:SIBN) by 2.8% during the fourth quarter, HoldingsChannel reports. The firm owned 2,720,824 shares of the company’s stock after selling 79,249 shares during the quarter. Champlain Investment Partners LLC owned 0.06% of SI-BONE worth $38,146,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. FMR LLC lifted its stake in shares of SI-BONE by 103.6% in the 3rd quarter. FMR LLC now owns 2,354 shares of the company’s stock valued at $33,000 after purchasing an additional 1,198 shares in the last quarter. Mainstream Capital Management LLC purchased a new stake in shares of SI-BONE during the 4th quarter valued at about $53,000. R Squared Ltd acquired a new position in SI-BONE during the 4th quarter worth approximately $73,000. KLP Kapitalforvaltning AS purchased a new position in shares of SI-BONE in the fourth quarter valued at $97,000. Finally, Proficio Capital Partners LLC purchased a new position in SI-BONE in the 4th quarter valued at about $155,000. 98.11% of the stock is currently owned by hedge funds and other institutional investors.

SI-BONE Stock Up 3.9 %

Shares of SI-BONE stock opened at $13.85 on Friday. The company has a quick ratio of 7.22, a current ratio of 8.25 and a debt-to-equity ratio of 0.22. The business has a 50-day moving average price of $15.33 and a 200 day moving average price of $14.62. SI-BONE, Inc. has a fifty-two week low of $11.70 and a fifty-two week high of $19.16. The firm has a market cap of $587.97 million, a P/E ratio of -15.05 and a beta of 1.02.

SI-BONE (NASDAQ:SIBN) last posted its quarterly earnings results on Monday, February 24th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.05. The business had revenue of $49.00 million for the quarter, compared to analyst estimates of $48.87 million. SI-BONE had a negative return on equity of 22.51% and a negative net margin of 23.82%. On average, sell-side analysts forecast that SI-BONE, Inc. will post -0.78 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

SIBN has been the topic of several recent analyst reports. Truist Financial reiterated a “buy” rating and issued a $22.00 price target (up previously from $18.00) on shares of SI-BONE in a research note on Tuesday, February 25th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $25.00 target price on shares of SI-BONE in a research report on Tuesday, February 25th. Finally, Needham & Company LLC raised their price target on shares of SI-BONE from $20.00 to $24.00 and gave the stock a “buy” rating in a research report on Tuesday, February 25th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $24.40.

Insider Transactions at SI-BONE

In other SI-BONE news, SVP Michael A. Pisetsky sold 3,128 shares of the firm’s stock in a transaction on Wednesday, April 2nd. The stock was sold at an average price of $14.14, for a total value of $44,229.92. Following the sale, the senior vice president now directly owns 244,878 shares in the company, valued at approximately $3,462,574.92. This trade represents a 1.26 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Anthony J. Recupero sold 3,311 shares of the business’s stock in a transaction on Wednesday, April 2nd. The shares were sold at an average price of $14.15, for a total transaction of $46,850.65. Following the transaction, the insider now directly owns 284,555 shares of the company’s stock, valued at approximately $4,026,453.25. This trade represents a 1.15 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 6,776 shares of company stock worth $96,644. 3.90% of the stock is currently owned by insiders.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.